Literature DB >> 8051222

A study of human reovirus IgG and IgA antibodies by ELISA and western blot.

B Selb1, B Weber.   

Abstract

Immunoglobulin A and G reactivities to human reovirus were investigated comparatively by Western blot and ELISA in a collection of 120 serum samples. Five different reovirus polypeptides of molecular weights of 127, 79, 54 42 and 40 kDa were visualized by polyacrylamide gel electrophoresis. Of 80 anti-reovirus ELISA-IgG positive serum samples, 97.5% and 15.0% reacted with one or more virus-specific bands in the IgG and IgA Western blot respectively. The 127 and 79 kDa proteins reacted with 100% and 96.2% of the IgG Western blot-positive serum samples (n = 78). IgG reactivities to the 40, 54 and 42 kDa proteins were detected in 96.2%, 80.8% and 20.5% of the immunoblot-positive sera. Compared to the Western blot, the ELISA had a specificity of 94.9% for IgG and 96.3% for IgA detection. The sensitivity of specific IgG and IgA detection by ELISA were 96.3% and 100%, respectively. Using the ELISA, a seroepidemiological survey was carried out on 850 sera collected from October 1989 to September 1992. The overall prevalence of reovirus IgG and IgA antibodies were 53.5% and 15.5% respectively. An age dependent increase of the seroprevalence of anti-reovirus IgG was observed. In contrast, the prevalence of IgA antibodies remained constant during childhood. Seroprevalence peak levels were observed in the 9-11, 20-29, 40-49 and > or = 60 years age group. The results of the study suggest that antireovirus IgG antibodies may persist lifelong, whereas IgA antibodies are detectable for a short time and may indicate a recent reovirus infection. The development of a sensitive and specific ELISA assay for the detection of class-specific immunoglobulins permits further investigation of reovirus infections and may contribute to improving the serological diagnosis of recent infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8051222     DOI: 10.1016/0166-0934(94)90062-0

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  32 in total

Review 1.  Mucosal T cell response to reovirus.

Authors:  D Chen; D H Rubin
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Myocarditis associated with reovirus infection.

Authors:  F Terheggen; E Benedikz; P H J Frissen; K Brinkman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-01       Impact factor: 3.267

3.  A potentially novel reovirus isolated from swine in northeastern China in 2007.

Authors:  Chaofan Zhang; Licheng Liu; Pengzhi Wang; Shanshan Liu; Wencheng Lin; Feng Hu; Weili Wu; Weijun Chen; Shangjin Cui
Journal:  Virus Genes       Date:  2011-07-15       Impact factor: 2.332

4.  Reovirus-Induced Apoptosis in the Intestine Limits Establishment of Enteric Infection.

Authors:  Judy J Brown; Sarah P Short; Jennifer Stencel-Baerenwald; Kelly Urbanek; Andrea J Pruijssers; Nicole McAllister; Mine Ikizler; Gwen Taylor; Pavithra Aravamudhan; Solomiia Khomandiak; Bana Jabri; Christopher S Williams; Terence S Dermody
Journal:  J Virol       Date:  2018-04-27       Impact factor: 5.103

5.  Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.

Authors:  Robert A Adair; Victoria Roulstone; Karen J Scott; Ruth Morgan; Gerard J Nuovo; Martin Fuller; Deborah Beirne; Emma J West; Victoria A Jennings; Ailsa Rose; Joan Kyula; Sheila Fraser; Rajiv Dave; David A Anthoney; Alison Merrick; Robin Prestwich; Amer Aldouri; Oliver Donnelly; Hardev Pandha; Matt Coffey; Peter Selby; Richard Vile; Giles Toogood; Kevin Harrington; Alan A Melcher
Journal:  Sci Transl Med       Date:  2012-06-13       Impact factor: 17.956

6.  Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.

Authors:  V Roulstone; K Twigger; S Zaidi; T Pencavel; J N Kyula; C White; M McLaughlin; R Seth; E M Karapanagiotou; D Mansfield; M Coffey; G Nuovo; R G Vile; H S Pandha; A A Melcher; K J Harrington
Journal:  Gene Ther       Date:  2012-08-16       Impact factor: 5.250

7.  Mycophenolic acid inhibits replication of Type 2 Winnipeg, a cerebrospinal fluid-derived reovirus isolate.

Authors:  Laura L Hermann; Kevin M Coombs
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-09       Impact factor: 2.471

8.  Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor.

Authors:  Masaya Igase; Chung Chew Hwang; Satoshi Kambayashi; Masato Kubo; Matt Coffey; Takako Shimokawa Miyama; Kenji Baba; Masaru Okuda; Shunsuke Noguchi; Takuya Mizuno
Journal:  Can J Vet Res       Date:  2016-01       Impact factor: 1.310

9.  Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.

Authors:  Radharani Gollamudi; Mohammad H Ghalib; Kavita K Desai; Imran Chaudhary; Benny Wong; Mark Einstein; Matthew Coffey; George M Gill; Karl Mettinger; John M Mariadason; Sridhar Mani; Sanjay Goel
Journal:  Invest New Drugs       Date:  2009-07-02       Impact factor: 3.850

10.  Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.

Authors:  F Errington; C L White; K R Twigger; A Rose; K Scott; L Steele; L J Ilett; R Prestwich; H S Pandha; M Coffey; P Selby; R Vile; K J Harrington; A A Melcher
Journal:  Gene Ther       Date:  2008-04-10       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.